FrancophonIA/ELRC3.0 huggingface dataset:
English: Not known Macular oedema, eyelid ptosis, lid sulcus deepened, iris hyperpigmentation, corneal disorder
Croatian: Edem makule, ptoza vjeđe, produbljivanje sulkusa vjeđa, hiperpigmentacija šarenice, poremećaj rožnice
English: Arrhythmia, heart rate irregular Not known Cardiac failure, tachycardia, chest pain, palpitations
Croatian: Zatajenje srca, tahikardija, bol u prsištu, palpitacije
English: • eye inflammation.
Croatian: Poremećaji oka
English: Do not drive or use machines until this has worn off.
Croatian: Sve dok ove smetnje ne nestanu treba izbjegavati upravljanje vozilima i strojevima.
English: 3 x 2.5 ml - PP bottle
Croatian: 3 x 2,5 ml - bočica od polipropilena
English: Gastrointestinal: taste disturbances, nausea, indigestion, diarrhoea, dry mouth, abdominal pain, vomiting and constipation.
Croatian: Probavni sustav: poremećaj okusa, mučnina, loša probava, proljev, suhoća usta, bol u trbuhu, povraćanje i zatvor.
English: Common side effects (may affect up to 1 in 10 people) Effects in the eye
Croatian: Česte nuspojave (mogu se pojaviti u manje od 1 na 10 osoba) Nuspojave na oku
English: 6 x 2.5 ml - PP bottle
Croatian: 6 x 2,5 ml - bočica od polipropilena
English: Uncommon side effects (may affect up to 1 in 100 people) Effects in the eye
Croatian: Manje česte nuspojave (mogu se pojaviti u manje od 1 na 100 osoba) Nuspojave na oku
English: 1 x 2.5 ml - PP bottle
Croatian: 1 x 2,5 ml - bočica od polipropilena
English: Ocular effects
Croatian: Hiperemija oka
English: Asthenia
Croatian: Dojenje
English: Droopy eyelid (making the eye stay half closed), sunken eyes (eyes appear more inset), changes in the colour of the iris (coloured part of the eye).
Croatian: Spuštena vjeđa (zbog čega je oko poluzatvoreno), utonule oči (izgled upalih očiju), promjena boje šarenice (obojenog dijela oka).
English: Alanine aminotransferase increased, aspartate aminotransferase increased
Croatian: Povišenje vrijednosti alanin aminotransferaze, povišenje vrijednosti aspartat aminotransferaze Poremećaji kože i potkožnog tkiva Manje često Kontaktni dermatitis, hipertrihoza, hiperpigmentacija kože (periokularno)
English: Excipients
Croatian: Puurs
English: OVERWRAP
Croatian: Nuspojave
English: 6 x 2.5 ml - LDPE bottle
Croatian: 6 x 2,5 ml - bočica od polietilena niske gustoće
English: 1 x 2.5 ml - LDPE bottle
Croatian: 1 x 2,5 ml - bočica od polietilena niske gustoće
English: 3 x 2.5 ml - LDPE bottle
Croatian: 3 x 2,5 ml - bočica od polietilena niske gustoće
English: Uncommon Dyspnoea, postnasal drip Rare
Croatian: Psorijatični osip ili egzacerbacija psorijaze
English: The main measure of effectiveness was the change in the levels of haemoglobin between the start of the study and the evaluation period, between weeks 25 and 29.
Croatian: Glavna mjera djelotvornosti bila je promjena u koncentracijama hemoglobina između početka ispitivanja i razdoblja ocjene, između 25. i 29. tjedna.
English: This summary was last updated in 04-2016.
Croatian: Ovaj pregled informacija posljednji je put ažuriran u 08. 2018.
English: The full EPAR for Epoetin Alfa Hexal can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Više informacija o lijeku Epoetin Alfa Hexal možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: When Epoetin Alfa Hexal is used for autologous blood transfusion, the restrictions normally associated with this type of transfusion should be observed.
Croatian: Kada se Epoetin Alfa Hexal koristi za autolognu transfuziju krvi, valja se pridržavati ograničenja koja su uobičajeno povezana s ovom vrstom transfuzije.
English: The iron levels of all patients should be checked before treatment to make sure that they are not too low, and iron supplements should be used throughout treatment.
Croatian: Koncentracije željeza svih bolesnika trebaju biti provjerene kako bi se osiguralo da nisu preniske, a tijekom terapije trebaju se koristiti dodatci željeza.
English: For patients with kidney failure or receiving chemotherapy, haemoglobin levels should remain within the recommended range (between 10 and 12 grams per decilitre in adults and between 9.5 and 11 g/dl in children).
Croatian: Za bolesnike sa zatajenjem bubrega, bolesnike s mijelodisplastičnim sindromima ili bolesnike koji primaju kemoterapiju koncentracije hemoglobina trebaju ostati unutar preporučenog raspona (između 10 i 12 grama po decilitru u odraslih osoba i između 9,5 i 11 g/dl u djece).
English: It is used in patients with normal blood iron levels who could experience complications if they were to receive a blood transfusion, if they do not have the opportunity to donate their own blood before surgery and are expected to lose 900 to 1,800 ml of blood.
Croatian: Primjenjuje se u bolesnika s normalnim koncentracijama željeza u krvi koji bi mogli imati komplikacije ako prime transfuzije krvi, u slučaju da nemaju prilike donirati vlastitu krv prije kirurškog zahvata, i za koje se očekuje da će izgubiti 900 do 1 800 ml krvi;
English: • patients undergoing surgery who cannot receive medicines for the prevention of blood clots.
Croatian: • bolesnika koji idu na kirurški zahvat, a koji ne mogu primati lijekove za prevenciju krvnih ugrušaka;
English: The most common side effects with Epoetin Alfa Hexal (seen in more than 1 patient in 10) are nausea (feeling sick), diarrhoea, vomiting, pyrexia (fever) and headache.
Croatian: Najčešće nuspojave lijeka Epoetin Alfa Hexal (koje se mogu javiti u više od 1 na 10 osoba) jesu mučnina, proljev, povraćanje, vrućica i glavobolja.
English: • to treat anaemia (low red blood cell counts) that is causing symptoms in patients with ‘chronic kidney failure' (long-term, progressive decrease in the ability of the kidneys to work properly) or other kidney problems;
Croatian: • za liječenje anemije (malog broja crvenih krvnih stanica) koja uzrokuje simptome u bolesnika s „kroničnim zatajenjem bubrega” (dugoročnim, progresivnim smanjenjem sposobnosti bubrega da ispravno funkcioniraju) ili drugim problemima s bubrezima;
English: For more information on biosimilar medicines, see the question-and-answer document here.
Croatian: Više informacija o biosličnim lijekovima potražite ovdje.
English: • to increase the amount of blood that can be taken in adult patients with moderate anaemia and normal blood iron levels who are going to have an operation and donate their own blood before surgery (autologous blood transfusion);
Croatian: • za povećanje količine krvi koju mogu primiti odrasli bolesnici s umjerenom anemijom i normalnim koncentracijama željeza u krvi koji idu na operaciju i doniraju svoju krv prije kirurškog zahvata (autologna transfuzija krvi);
English: In patients receiving chemotherapy or with kidney problems, anaemia can be caused by a lack of erythropoietin, or by the body not responding enough to the erythropoietin it has naturally.
Croatian: Kod bolesnika koji primaju kemoterapiju ili imaju problema s bubrezima anemiju može uzrokovati manjak eritropoetina ili organizam koji ne reagira adekvatno na eritropoetin koji se prirodno nalazi u tijelu.
English: All of the patients had been receiving Eprex/Erypo injected into a vein for at least eight weeks before they were either switched to Epoetin Alfa Hexal or remained on Eprex/Erypo.
Croatian: Svi bolesnici primali su Eprex/Erypo ubrizgan u venu tijekom najmanje 8 tjedana prije nego su prešli na Epoetin Alfa Hexal ili su nastavili uzimati Eprex/Erypo.
English: • patients who have developed pure red cell aplasia (reduced or stopped red blood cell production) following treatment with any erythropoietin;
Croatian: • bolesnika koji su razvili čistu aplaziju crvenih krvnih stanica (smanjena proizvodnja crvenih krvnih stanica ili prestanak njihove proizvodnje) nakon terapije eritropoetinom;
English: What measures are being taken to ensure the safe and effective use of Epoetin Alfa Hexal?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Epoetin Alfa Hexal?
English: Epoetin Alfa Hexal must not be used in the following groups:
Croatian: Epoetin Alfa Hexal ne smije se koristiti u sljedećih grupa bolesnika:
English: It must not be used in patients about to undergo major orthopaedic surgery who have severe cardiovascular (heart and blood vessel) problems including a recent heart attack or stroke.
Croatian: • bolesnika koji će uskoro biti podvrgnuti većom ortopedskom kirurškom zahvatu i imaju ozbiljne kardiovaskularne probleme (probleme sa srcem i krvnim žilama), uključujući i nedavni infarkt miokarda ili moždani udar.
English: The active substance in Epoetin Alfa Hexal, epoetin alfa, is a copy of a hormone called erythropoietin, and works in exactly the same way as the natural hormone to stimulate the production of red blood cells from the bone marrow.
Croatian: Djelatna tvar lijeka Epoetin Alfa Hexal, epoetin alfa, kopija je hormona naziva eritropoetin i djeluje na potpuno isti način kao prirodni hormon za stimulaciju proizvodnje crvenih krvnih stanica iz leđne moždine.
English: The dose, the frequency of injection and how long it is used for also depend on why Epoetin Alfa Hexal is being used and on the patient's bodyweight, and are adjusted according to the patient's response.
Croatian: Doza, učestalost injektiranja i trajanje primjene također ovise o razlogu primjene lijeka Epoetin Alfa Hexal i tjelesnoj težini bolesnika te se primjenjuju u skladu s odgovorom bolesnika.
English: The reference medicine for Epoetin Alfa Hexal is Eprex/Erypo.
Croatian: Referentni lijek za Epoetin Alfa Hexal je Eprex/Erypo.
English: Epoetin Alfa Hexal, injected into a vein, was compared with the reference medicine in one main study involving 479 patients with anaemia caused by kidney problems.
Croatian: Epoetin Alfa Hexal ubrizgan u venu uspoređen je s referentnim lijekom u jednom glavnom ispitivanju koje je obuhvaćalo 479 bolesnika s anemijom uzrokovanom bubrežnim problemima.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Epoetin Alfa Hexal on 28 August 2007.
Croatian: Lijek Epoetin Alfa Hexal dobio je odobrenje za stavljanje lijeka u promet koje vrijedi na prostoru EU-a od 28. kolovoza 2007.
English: For more information about treatment with Epoetin Alfa Hexal, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Epoetin Alfa Hexal pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: Epoetin Alfa Hexal is given as an injection into a vein or as an injection under the skin, depending on the condition for which the patient is being treated.
Croatian: Lijek Epoetin Alfa Hexal dostupan je u obliku prethodno napunjenih štrcaljki različitih jakosti i daje se kao injekcija u venu ili injekcija pod kožu, ovisno o stanju za koje se bolesnika liječi.
English: Epoetin Alfa Hexal was as effective as Eprex/Erypo in increasing and maintaining red blood cell counts.
Croatian: Nadalje, u nekoliko se ispitivanja pokazalo da je Epoetin Alfa Hexal jednako učinkovit kao Eprex/Erypo u povećanju i zadržavanju broja crvenih krvnih stanica.
English: This means that Epoetin Alfa Hexal is similar to and contains the same active substance as a biological medicine that is already authorised in the European Union (EU), which is known as the ‘reference medicine'.
Croatian: Drugim riječima, Epoetin Alfa Hexal je vrlo sličan drugom biološkom lijeku („referentni lijek”) koji je već odobren u EU-u.
English: Other information about Epoetin Alfa Hexal
Croatian: Ostale informacije o lijeku Epoetin Alfa Hexal
English: Treatment with Epoetin Alfa Hexal must be started under the supervision of a doctor who has experience in the management of patients with the conditions that the medicine is used for.
Croatian: Epoetin Alfa Hexal izdaje se samo na liječnički recept, a liječenje se mora započeti pod nadzorom liječnika koji ima iskustva u liječenju bolesnika sa stanjima za koje se Epoetin Alfa Hexal primjenjuje.
English: What is the risk associated with Epoetin Alfa Hexal?
Croatian: Koji su rizici povezani s lijekom Epoetin Alfa Hexal?
English: Epoetin Alfa Hexal is a ‘biosimilar' medicine.
Croatian: Epoetin Alfa Hexal sadrži djelatnu tvar epoetin alfa te je „biosličan lijek”.
English: In these cases, epoetin alfa is used to replace the missing hormone or to increase red blood cell counts.
Croatian: U tim slučajevima epoetin alfa koristi se za povećanje broja crvenih krvnih stanica.
English: A further study looked at the effects of Epoetin Alfa Hexal given under the skin in 416 patients with chronic kidney failure.
Croatian: Dodatno ispitivanje pokazalo je da je lijek Epoetin Alfa Hexal siguran i djelotvoran kada se ubrizgavao pod kožu u 416 bolesnika s kroničnim zatajenjem bubrega.
English: Epoetin Alfa Hexal is used for the following:
Croatian: Epoetin Alfa Hexal je lijek koji se koristi za sljedeće:
English: For the full list of all side effects reported with Epoetin Alfa Hexal, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Epoetin Alfa Hexal potražite u uputi o lijeku.
English: In the study of patients with anaemia caused by kidney problems, patients switching to Epoetin Alfa Hexal maintained haemoglobin levels to the same extent as those continuing to take Eprex/Erypo.
Croatian: Bolesnici koji su počeli uzimati lijek Epoetin Alfa Hexal zadržali su razine hemoglobina u istoj mjeri kao i bolesnici koji su nastavili uzimati lijek Eprex/Erypo.
English: Therefore, the CHMP's view was that, as for Eprex/Erypo, the benefit outweighs the identified risks.
Croatian: Stoga je stav Agencije da koristi lijeka Epoetin Alfa Hexal, kao i kod lijeka Eprex/Erypo, nadmašuje utvrđeni rizik te da lijek može biti odobren.
English: The company also presented the results of a study comparing the effects of Epoetin Alfa Hexal injected under the skin with those of Eprex/Erypo in 114 cancer patients who were receiving chemotherapy.
Croatian: Drugo ispitivanje također je pokazalo da je lijek Epoetin Alfa Hexal ubrizgan pod kožu bio jednako učinkovit u zadržavanju razina hemoglobina kao i Eprex/Erypo u 114 bolesnika s karcinomom koji su primali kemoterapiju.
English: The CHMP concluded that, in accordance with EU requirements, Epoetin Alfa Hexal has been shown to have a comparable quality, safety and efficacy profile to Eprex/Erypo.
Croatian: Europska agencija za lijekove zaključila je kako, u skladu sa zahtjevima EU-a za bioslične lijekove, lijek Epoetin Alfa Hexal ima vrlo sličnu strukturu, čistoću i biološku aktivnost kao i lijek Eprex/Erypo te se u tijelu raspoređuje na isti način.
English: Why has Epoetin Alfa Hexal been approved?
Croatian: Zašto je lijek Epoetin Alfa Hexal odobren u EU-u?
English: What is Epoetin Alfa Hexal used for?
Croatian: Što je Epoetin Alfa Hexal i za što se koristi?
English: What benefit has Epoetin Alfa Hexal shown during the studies?
Croatian: Koje su koristi lijeka Epoetin Alfa Hexal utvrđene u ispitivanjima?
English: How does Epoetin Alfa Hexal work?
Croatian: Kako djeluje Epoetin Alfa Hexal?
English: How is Epoetin Alfa Hexal used?
Croatian: Kako se Epoetin Alfa Hexal koristi?
English: Epoetin Alfa Hexal was studied to show that it is comparable to the reference medicine, Eprex/Erypo.
Croatian: Ispitivanja su pokazala i da primjena lijeka Epoetin Alfa Hexal dovodi do slične razine djelatne tvari u tijelu kao i primjena lijeka Eprex/Erypo.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Epoetin Alfa Hexal, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Nuspojave prijavljene za lijek Epoetin Alfa Hexal pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: • hair loss (in most cases normal hair growth should return)
Croatian: • gubitak kose (u većini slučajeva trebao bi se vratiti normalan rast kose)
English: Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicine, including medicines obtained without a prescription.
Croatian: Molimo obavijestite svog liječnika ili ljekarnika ako uzimate ili ste nedavno uzeli bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta.
English: 1Full analysis set (intent-to-treat)
Croatian: 1 potpuna analiza (intent-to-treat)
English: Harmful for those suffering from alcoholism.
Croatian: Lijek može biti štetan za ljude koji pate od alkoholizma.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 31 January 2012
Croatian: Datum prvog odobrenja: 31. siječnja 2012.
English: Discuss with your doctor if you suffer from alcohol dependency or liver impairment.
Croatian: Razgovarajte sa svojim liječnikom ako ste ovisni o alkoholu ili imate narušenu funkciju jetre.
English: - if you have a severe liver disease.
Croatian: - ako bolujete od teške bolesti jetre.
English: • raised liver enzymes (hence the need for regular blood tests).
Croatian: • povišeni jetreni enzimi (potrebne redovite krvne pretrage).
English: 2 Estimated median survival
Croatian: 2 procijenjeni medijan preživljenja
English: The first interim analysis was planned 3 years after the date when half of study enrollment was done.
Croatian: Prva privremena analiza planirala se provesti 3 godine nakon datuma pri kojem je polovica bolesnika uključena u studiju.
English: The safety and efficacy of docetaxel in nasopharyngeal carcinoma in children aged 1 month to less than 18 years have not yet been established.
Croatian: Sigurnost primjene i djelotvornost lijeka docetaksela u nazofaringealnom karcinomu u djece starosti od 1 mjeseca do 18 godina nije još ustanovljena.
English: You must not become pregnant during treatment with this medicine and must use an effective method of contraception during therapy, because Docetaxel Mylan may be harmful for the unborn baby.
Croatian: Ne smijete zatrudnjeti tijekom uzimanja ovog lijeka i morate provoditi učinkovite mjere kontracepcije tijekom liječenja, jer Docetaxel Mylan može biti štetan za nerođeno dijete.
English: Primary prophylactic G-CSF was made mandatory in TAC arm after 230 patients were randomized.
Croatian: Primarna G-CSF profilaksa uvedena je kao obavezna u TAC skupini nakon što je randomizirano 230 bolesnika.
English: During the infusion at the hospital the following allergic reactions (may affect more than 1 in 10 people):
Croatian: Tijekom infuzije u bolnici mogu se javiti sljedeće alergijske reakcije (mogu se javiti u više od 1 na 10 osoba):
English: Other medicines and Docetaxel Mylan
Croatian: Drugi lijekovi i Docetaxel Mylan
English: Cases of persisting alopecia have been reported.
Croatian: Prijavljeni su slučajevi perzistentne alopecije.
English: Your doctor may change the dose and frequency of dosing depending on your blood tests, your general condition and your response to Docetaxel Mylan.
Croatian: Vaš liječnik može mijenjati dozu i učestalost primjene lijeka ovisno o rezultatima krvnih pretraga, Vašem općem stanju i terapijskom odgovoru na Docetaxel Mylan.
English: Docetaxel Mylan will be given by infusion into one of your veins (intravenous use).
Croatian: Docetaxel Mylan ćete dobiti infuzijom u jednu od vena (intravenska primjena).
English: A total of 1006 patients with KPS ≥ 60 were randomized to the following treatment groups:
Croatian: Ukupno 1006 bolesnika s KPS > 60 randomizirani su prema liječenju u sljedeće skupine:
English: It is important that you read the entire contents of this guide prior to the preparation of the Docetaxel Mylan infusion solution.
Croatian: Važno je pročitati cijeli sadržaj upute prije pripreme Docetaxel Mylan infuzijske otopine.
English: Frequency unknown:
Croatian: Nepoznata učestalost:
English: If the patient continues to experience these reactions at 60 mg/m², the treatment should be discontinued.
Croatian: Ako se u bolesnika pri primjeni doze od 60 mg/m i dalje javljaju ove reakcije, liječenje treba prekinuti.
English: Recommendations for the safe handling:
Croatian: Preporuke za sigurno rukovanje
English: Pharmacotherapeutic group: antineoplastic agents, taxanes, ATC Code: L01CD02
Croatian: Farmakoterapijska skupina: citostatici, taksani, ATK oznaka: L01CD02.
English: Before each treatment with Docetaxel Mylan, you will have blood tests to check that you have enough blood cells and sufficient liver function to receive Docetaxel Mylan.
Croatian: Prije svake primjene lijeka Docetaxel Mylan, obavit ćete krvne pretrage kako bi se provjerilo imate li dovoljno krvnih stanica te odgovarajuću funkciju jetre kako biste mogli primiti Docetaxel Mylan.
English: In about 20% of these cases there were no risk factors for acute renal failure concomitant nephrotoxic medicinal products and gastro-intestinal disorders.
Croatian: U otprilike 20% ovih slučajeva nije bilo faktora rizika za akutno zatajenje bubrega, kao što su istodobno primijenjeni nefrotoksični lijek i poremećaji probavnog sustava.
English: One patient in TAC arm died because of dilated cardiomyopathy.
Croatian: Jedan bolesnik u TAC skupini preminuo je zbog dilatacijske kardiomiopatije.
English: The following information is intended for healthcare professionals only: PREPARATION GUIDE FOR USE WITH DOCETAXEL MYLAN CONCENTRATE FOR SOLUTION FOR INFUSION
Croatian: Sljedeće informacije namijenjene su samo zdravstvenim djelatnicima: UPUTE ZA PRIPREMU I UPOTREBU DOCETAXEL MYLAN KONCENTRATA ZA OTOPINU ZA INFUZIJU
English: Docetaxel Mylan contains alcohol.
Croatian: Docetaxel Mylan sadrži alkohol.
English: The survival rate was 93.7% in the TAC arm and 91.4 % in the FAC arm, at the 8-year follow-up timepoint, and 91.3 % in the TAC arm and 89% in the FAC arm, at the 10-year follow-up timepoint.
Croatian: Stopa preživljenja bila je 93,7% u TAC skupini i 91,4% u FAC skupini, u točki praćenja od 8 godina te 91,3% u TAC skupini i 89% u FAC skupini, u točki praćenja od 10 godina.
English: 117 allée des Parcs F-69 800 Saint Priest France
Croatian: 117 allée des Parcs F-69 800 Saint Priest Francuska
English: To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy.
Croatian: Gore navedeno treba uzeti u obzir kod trudnica, dojilja, djece i visoko rizičnih skupina bolesnika, kao što su bolesnici s bolešću jetre ili epilepsijom.
English: More than one vial may be necessary to obtain the required dose for the patient.
Croatian: Ponekad je potrebno upotrijebiti više od jedne bočice kako bi se dobila potrebna doza za bolesnika.
English: The onset of moderate and severe retention is delayed (median cumulative dose: 818.9 mg/m²) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m²); however, it has been reported in some patients during the early courses of therapy.
Croatian: Pojava umjerene i teške retencije je odgođena (medijan kumulativne doze: 818,9 mg/m2) u bolesnika koji su primili premedikaciju u odnosu na bolesnike koji nisu primili premedikaciju (medijan kumulativne doze: 489,7 mg/m2); retencija je, međutim, bila zabilježena u nekih bolesnika tijekom ranog stupnja liječenja.
English: ER/PR-negative or Grade 3 or tumor size >5 cm
Croatian: PR = progesteronski receptor a ER/PR-negativni ili gradus 3 ili veličina tumora >5 cm
English: • blurred vision due to swelling of the retina within the eye (cystoid macular oedema) • decrease of the sodium in your blood.
Croatian: • zamagljen vid zbog oticanja mrežnice unutar oka (cistični edem makule) • smanjena razina natrija u krvi.
English: See the leaflet for further information.
Croatian: Vidjeti Uputu o lijeku za detaljnije informacije.
English: The ORR was 59.3% (95% CI: 52.8-65.9) in AT arm versus 46.5% (95% CI: 39.8-53.2) in AC arm.
Croatian: ORR je bio 59,3 % (95% CI: 52,8-65,9) u AT skupini u odnosu na 46,5% (95% CI: 39,8-53,2) u AC skupini.